Close Menu

NEW YORK (GenomeWeb) – Abbott has entered into a definitive agreement to acquire Alere for $5.8 billion, the companies said today.

"The combination of Alere and Abbott will create the world's premier point-of-care testing business and significantly strengthen and grow Abbott's diagnostics presence," Miles White, Abbott's chairman and CEO, said in a statement.

On a conference call to discuss the transaction, he also noted, "The trends in point-of-care testing, which we're well aware of, make this the right time to make the move."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.